{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:20Z","timestamp":1788931220978,"version":"build-2803163510"},"reference-count":35,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,5,26]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Used for a wide range of cancers, nivolumab has been reported to cause immune-related adverse events, including isolated adrenocorticotropic hormone deficiency (IAD). We report an 81-year-old woman with malignant mesothelioma who presented with abdominal pain after eight courses of nivolumab therapy, leading to the diagnosis of nivolumab-induced IAD. We should consider adrenal insufficiency (AI) when a patient on nivolumab complains of abdominal pain and has no other explanatory findings. Infusion-resistant hypotension and hyponatraemia can further suggest AI.<\/jats:p>","DOI":"10.1136\/bcr-2021-243093","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T13:02:17Z","timestamp":1626872537000},"page":"e243093","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-3793","authenticated-orcid":false,"given":"Koichi","family":"Hata","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Kyoto Respiratory Center, Rakuwakai Otowa Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2025082701234255000_14.7.e243093.1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040"},{"key":"2025082701234255000_14.7.e243093.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"2025082701234255000_14.7.e243093.3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.12659\/AJCR.909584","article-title":"Nivolumab immunotherapy in malignant mesothelioma: a case report highlighting a new opportunity for exceptional outcomes","volume":"19","author":"Jones","year":"2018","journal-title":"Am J Case Rep"},{"key":"2025082701234255000_14.7.e243093.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025082701234255000_14.7.e243093.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.002"},{"key":"2025082701234255000_14.7.e243093.6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025082701234255000_14.7.e243093.7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.gendis.2016.10.002","article-title":"Immune-Related endocrine disorders in novel immune checkpoint inhibition therapy","volume":"3","author":"Min","year":"2016","journal-title":"Genes Dis"},{"key":"2025082701234255000_14.7.e243093.8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-006-0408-5"},{"key":"2025082701234255000_14.7.e243093.9","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366"},{"key":"2025082701234255000_14.7.e243093.10","unstructured":"List of side effects of nivolumab reported in all types of cancers from 4 July 2014 to 31 January 2021., 2021. Available: https:\/\/www.opdivo.jp\/system\/files\/2021-02\/side_effect.pdf[Accessed 20 Feb 2021]."},{"key":"2025082701234255000_14.7.e243093.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(95)80024-7"},{"key":"2025082701234255000_14.7.e243093.12","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00005"},{"key":"2025082701234255000_14.7.e243093.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2014.01.006"},{"key":"2025082701234255000_14.7.e243093.14","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181db6b7a"},{"key":"2025082701234255000_14.7.e243093.15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","article-title":"Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]","volume":"64","author":"Cho","year":"2017","journal-title":"Endocr J"},{"key":"2025082701234255000_14.7.e243093.16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230848","article-title":"Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barr\u00e9 syndrome occurring in a patient treated with nivolumab","volume":"12","author":"Pierrard","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025082701234255000_14.7.e243093.17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.anl.2019.02.005","article-title":"Pituitary-Adrenal dysfunction caused by nivolumab for head and neck cancer","volume":"46","author":"Hihara","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"2025082701234255000_14.7.e243093.18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","article-title":"Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer","volume":"47","author":"Kagoshima","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"2025082701234255000_14.7.e243093.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J Med Case Rep"},{"key":"2025082701234255000_14.7.e243093.20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fulminant type 1 diabetes associated with isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"key":"2025082701234255000_14.7.e243093.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-Onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"2025082701234255000_14.7.e243093.22","first-page":"223","article-title":"A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency","volume":"26","author":"Sato","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"2025082701234255000_14.7.e243093.23","first-page":"304","article-title":"Isolated adrenocorticotropic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: a case report","volume":"10","author":"Furubayashi","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025082701234255000_14.7.e243093.24","first-page":"391","article-title":"[A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea]","volume":"64","author":"Ito","year":"2018","journal-title":"Hinyokika Kiyo"},{"key":"2025082701234255000_14.7.e243093.25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225048","article-title":"Delayed presentation of isolated adrenocorticotropin insufficiency after nivolumab therapy for advanced non-small-cell lung carcinoma (NSCLC)","volume":"28","author":"Shrotriya","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2025082701234255000_14.7.e243093.26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/jocmr3257w","article-title":"Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma","volume":"10","author":"Takebayashi","year":"2018","journal-title":"J Clin Med Res"},{"key":"2025082701234255000_14.7.e243093.27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2340\/00015555-2902","article-title":"Isolated adrenocorticotropic hormone deficiency in melanoma patients treated with nivolumab","volume":"98","author":"Kitano","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2025082701234255000_14.7.e243093.28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to Nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review","volume":"57","author":"Ohara","year":"2018","journal-title":"Intern Med"},{"key":"2025082701234255000_14.7.e243093.29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008426","article-title":"Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review","volume":"96","author":"Zeng","year":"2017","journal-title":"Medicine"},{"key":"2025082701234255000_14.7.e243093.30","first-page":"115","article-title":"Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma","volume":"42","author":"Seki","year":"2017","journal-title":"Tokai J Exp Clin Med"},{"key":"2025082701234255000_14.7.e243093.31","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","article-title":"Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer","volume":"56","author":"Takaya","year":"2017","journal-title":"Intern Med"},{"key":"2025082701234255000_14.7.e243093.32","first-page":"4229","article-title":"Adrenal insufficiency related to Anti-Programmed death-1 therapy","volume":"37","author":"Ariyasu","year":"2017","journal-title":"Anticancer Res"},{"key":"2025082701234255000_14.7.e243093.33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jjco\/hyx018","article-title":"Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab","volume":"47","author":"Kitajima","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2025082701234255000_14.7.e243093.34","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231236","article-title":"Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency","volume":"12","author":"Martins Machado","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025082701234255000_14.7.e243093.35","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.13571","article-title":"Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy","volume":"44","author":"Narahira","year":"2017","journal-title":"J Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:23:54Z","timestamp":1756283034000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bcr-2021-243093"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243093","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}